News

Nasdaq2y
PD Factor-Based Stock Analysis - Nasdaq
PD Factor-Based Stock Analysis June 28, 2023 — 12:06 pm EDT Written by John Reese for Validea -> ...
Nasdaq4y
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors - Nasdaq
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the ...
Yahoo Finance10mon
PagerDuty Inc (PD) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
PagerDuty Inc (NYSE:PD) is set to release its Q2 2025 earnings on Sep 3, 2024. The consensus estimate for Q2 2025 revenue is $116.48 million, and the earnings are expected to come in at -$0.21 per ...
The Globe and Mail4y
Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology - The ...
AUSTIN, Texas, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company ...
CIO5y
What is gap analysis? Uncovering the missing links to successful performance - CIO
Gap analysis is a method of comparing the actual level of performance versus the desired level of performance for a business process, project, strategy or IT solution. Gap analysis, sometimes ...
Morningstar2mon
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD ...
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced ...
Yahoo Finance4y
Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors - Yahoo Finance
AUSTIN, Texas, July 09, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the ...